A detailed history of Pekin Hardy Strauss, Inc. transactions in Ardelyx, Inc. stock. As of the latest transaction made, Pekin Hardy Strauss, Inc. holds 546,410 shares of ARDX stock, worth $2.45 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares
546,410
Previous 531,660 2.77%
Holding current value
$2.45 Million
Previous $3.94 Million 4.44%
% of portfolio
0.5%
Previous 0.56%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$5.28 - $7.57 $77,880 - $111,657
14,750 Added 2.77%
546,410 $3.76 Million
Q2 2024

Aug 09, 2024

SELL
$5.89 - $9.31 $64,790 - $102,410
-11,000 Reduced 2.03%
531,660 $3.94 Million
Q1 2024

May 02, 2024

SELL
$6.05 - $9.74 $1.38 Million - $2.23 Million
-228,707 Reduced 29.65%
542,660 $3.96 Million
Q4 2023

Feb 05, 2024

SELL
$3.29 - $6.64 $171,589 - $346,309
-52,155 Reduced 6.33%
771,367 $4.78 Million
Q3 2023

Nov 07, 2023

SELL
$3.3 - $4.83 $1.22 Million - $1.79 Million
-370,600 Reduced 31.04%
823,522 $3.36 Million
Q2 2023

Aug 08, 2023

SELL
$3.23 - $4.95 $154,232 - $236,362
-47,750 Reduced 3.85%
1,194,122 $4.05 Million
Q1 2023

May 08, 2023

SELL
$2.68 - $4.79 $1.15 Million - $2.05 Million
-427,876 Reduced 25.63%
1,241,872 $5.95 Million
Q4 2022

Feb 13, 2023

SELL
$1.22 - $2.85 $341,008 - $796,617
-279,515 Reduced 14.34%
1,669,748 $4.76 Million
Q3 2022

Nov 09, 2022

BUY
$0.59 - $1.44 $125,733 - $306,875
213,108 Added 12.27%
1,949,263 $2.32 Million
Q2 2022

Aug 05, 2022

BUY
$0.51 - $1.17 $1,537 - $3,527
3,015 Added 0.17%
1,736,155 $1.02 Million
Q1 2022

May 13, 2022

BUY
$0.65 - $1.18 $148,170 - $268,986
227,955 Added 15.14%
1,733,140 $1.85 Million
Q4 2021

Feb 08, 2022

BUY
$0.86 - $1.7 $204,440 - $404,127
237,722 Added 18.76%
1,505,185 $1.66 Million
Q3 2021

Nov 12, 2021

BUY
$1.27 - $8.17 $158,115 - $1.02 Million
124,500 Added 10.89%
1,267,463 $1.67 Million
Q2 2021

Aug 12, 2021

SELL
$6.55 - $8.98 $3.23 Million - $4.43 Million
-493,767 Reduced 30.17%
1,142,963 $8.66 Million
Q1 2021

May 13, 2021

BUY
$6.1 - $7.69 $362,498 - $456,985
59,426 Added 3.77%
1,636,730 $10.8 Million
Q4 2020

Feb 11, 2021

SELL
$5.05 - $7.1 $725,669 - $1.02 Million
-143,697 Reduced 8.35%
1,577,304 $10.2 Million
Q3 2020

Nov 12, 2020

BUY
$5.25 - $7.08 $863,346 - $1.16 Million
164,447 Added 10.56%
1,721,001 $9.04 Million
Q2 2020

Aug 10, 2020

SELL
$5.37 - $8.11 $1.37 Million - $2.08 Million
-255,963 Reduced 14.12%
1,556,554 $10.8 Million
Q1 2020

May 11, 2020

SELL
$4.35 - $8.79 $1.35 Million - $2.73 Million
-310,075 Reduced 14.61%
1,812,517 $10.3 Million
Q4 2019

Feb 12, 2020

BUY
$4.23 - $8.29 $346,140 - $678,370
81,830 Added 4.01%
2,122,592 $15.9 Million
Q3 2019

Nov 12, 2019

SELL
$2.15 - $6.28 $693,185 - $2.02 Million
-322,412 Reduced 13.64%
2,040,762 $9.59 Million
Q2 2019

Aug 12, 2019

SELL
$2.49 - $3.73 $869,333 - $1.3 Million
-349,130 Reduced 12.87%
2,363,174 $6.36 Million
Q1 2019

May 14, 2019

BUY
$1.88 - $3.35 $136,021 - $242,379
72,352 Added 2.74%
2,712,304 $7.59 Million
Q4 2018

Feb 12, 2019

BUY
$1.66 - $4.16 $2.72 Million - $6.83 Million
1,641,037 Added 164.28%
2,639,952 $4.73 Million
Q3 2018

Nov 02, 2018

BUY
$3.75 - $4.65 $3.75 Million - $4.64 Million
998,915 New
998,915 $4.35 Million

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $694M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Pekin Hardy Strauss, Inc. Portfolio

Follow Pekin Hardy Strauss, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pekin Hardy Strauss, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pekin Hardy Strauss, Inc. with notifications on news.